Reacción a "Orforglipron is more effective than semaglutide, according to a phase III clinical trial"

This study is eagerly awaited because type 2 diabetes affects a large proportion of the population and we need a treatment approach that is easier for patients. The benefits of subcutaneous GLP-1 in type 2 diabetes have already been clearly demonstrated.

The fact that oral formulations in a once-daily tablet are being sought could facilitate earlier use and enable us to reach more people, as well as facilitating treatment according to each patient's preference. In this regard, orforglipron is compared head-to-head with oral semaglutide. Remember that orforglipron is not a peptide, it is a small chemical that can be administered independently of food, which could facilitate its use because it is more convenient for the patient.

Here we see its superiority in terms of glycated haemoglobin, 1.91 versus 1.47, and also something very important in terms of weight loss. In type 2 diabetes, this is very important because the origin of type 2 diabetes and its progression depend greatly on fat mass. This superior weight loss of 8.2 versus 5.3 is clinically quite relevant.

Orforglipron has demonstrated superiority in this clinical trial, but also, being more potent, the side effects could be greater, especially gastrointestinal side effects such as nausea or vomiting, which may require us to have a more progressive dose titration.

This is very good news. Type 2 diabetes is a very prevalent disease. Having a variety of molecules that suit patient preferences will undoubtedly be key to success and addressing the metabolic cause of weight loss. Of course, it also demonstrates control of glycated haemoglobin as a measure of glycaemic control.